Cancer de la prostate métastatique hormono-sensible : Vers une personnalisation totale en 2026

Debate on current cancer treatments, recorded as part of the Gustave Roussy Chemotherapy Course 2026. 00:00:10 | Introduction: Prostate cancer in 2026 00:00:30 | Understanding metastatic hormone-sensitive prostate cancer (mHSPC) 00:01:13 | The evolution of treatments: From hormone therapy alone to intensification 00:01:40 | Patient stratification: Prognosis according to tumor volume (High vs. Low volume) 00:02:22 | Clinical history: The impact of chemotherapy (CHAARTED and STAMPEDE studies) 00:03:33 | The era of triplet therapies: Benefits of the PEACE-1 study and overall survival 00:05:00 | PSA Monitoring: A Major Prognostic Factor for Adapting Strategy 00:06:00 | Towards Therapeutic De-escalation: Adaptive Studies and Intermittent Treatment 00:07:30 | Precision Medicine: Targeted Therapies (Lutetium PSMA, PARP and AKT Inhibitors) 00:11:30 | Conclusion and Key Messages: Personalizing Care in 2026 Find all Gustave Roussy Chemotherapy Courses in French: https://www.coursdechimio.com/